A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine

Teva Investigational Site 88011, Shijiazhuang

Teva Investigational Site 88004, Beijing

Teva Investigational Site 88001, Beijing

Teva Investigational Site 88016, Shenyang

Teva Investigational Site 88008, Changchun

Teva Investigational Site 88009, Changchun

Teva Investigational Site 88026, Harbin

Teva Investigational Site 88021, Shanghaishi

Teva Investigational Site 88025, Shanghaishi

Teva Investigational Site 88015, Suzhou

Teva Investigational Site 88010, Lianyungang

Teva Investigational Site 88033, Rizhao

Teva Investigational Site 88024, Tianjin

Teva Investigational Site 88023, Tianjin

Teva Investigational Site 88017, Wenzhou

Teva Investigational Site 88019, Fuzhou

Teva Investigational Site 88029, Chongqing

Teva Investigational Site 88022, Changsha Shi

Teva Investigational Site 88030, Changsha Shi

Teva Investigational Site 88012, Wuhan

Teva Investigational Site 88006, Wuhan

Teva Investigational Site 88034, Zhengzhou

Teva Investigational Site 88020, Guangzhou

Teva Investigational Site 88031, Zhanjiang

Teva Investigational Site 88013, Guiyang

Teva Investigational Site 88003, Chengdu

Teva Investigational Site 88032, Xining

Teva Investigational Site 88005, Luoyang

Teva Investigational Site 88028, Baotou